OCTA and Glaucoma Progression in the Non-Human Primate
OCTA and Glaucoma Progression in the Non-Human Primate
批准号:
10649710
负责人:
Nimesh Bhikhu Patel
金额:
$55.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-08-01 至 2026-05-31
关键词:
3-DimensionalAgeAnatomyAngiographyAnimalsAutopsyBasement membraneBlindnessBlood VesselsBlood capillariesBlood flowCannulationsCell DensityClinicalDataData SetDiseaseDisease ProgressionEndothelial CellsEuthanasiaExperimental ModelsExposure toEyeEye diseasesFaceGlaucomaHealthHistologicHumanImageImmunohistochemistryIndividualIndividual DifferencesLeftMeasuresMetabolicMethodsModelingMonitorNatureOptic DiskOptical Coherence TomographyPapillaryPathologicPathologyPatientsPerfusionPericytesPerimetryPhysiologic Intraocular PressurePopulationPrevalenceProcessPropertyRadialRegulationRetinaRetinal Ganglion CellsRiskRisk FactorsScanningScanning Electron MicroscopyStructureTechnologyTestingThickThinnessTimeTissuesTransmission Electron MicroscopyVascular blood supplyVisionadaptive optics scanning laser ophthalmoscopyanterior chambercomparativedensitydisorder riskexperimental analysisexperimental studyhigh riskhuman subjectin vivoinnovationmaculaneuralnonhuman primateoptic nerve disorderperfusion imagingpressurereconstructionregional differenceresponseretinal damageretinal nerve fiber layervascular factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION
Glaucoma is a group of diseases that results in a pathological loss of retinal ganglion cells (RGC) and irreversible
vision loss. Increased intraocular pressure (IOP) is a major risk factor for glaucoma, but some individuals with
elevated pressures never develop disease, and others with low pressures progress to blindness. Similarly, in the
non-human primate experimental glaucoma model, animals with similar IOP profiles are shown to have
significant differences in the extent and rate of retinal nerve fiber layer (RNFL) thickness loss. Both clinical and
experimental models suggest that in addition to IOP, other factors need to be considered for glaucoma
progression. We hypothesize the variability in disease progression can be explained by vascular factors. The
retina is one of the most metabolic tissues in the body, and it is unknown if eyes with relatively lower vascular
volume, or eyes that show greater change in perfusion with changes in IOP are at greater risk of pathology.
Furthermore, although eyes with optic neuropathy have reduced vascular density, it remains unknown if there
are changes in retinal vasculature that precede RGC loss. Optical coherence tomography angiography (OCTA)
is a non-invasive method for three-dimensional vascular perfusion imaging. However, analysis of OCTA imaged
vasculature is based on slab projections, where the three-dimensional nature of tissue is lost. In addition, OCTA
vascular perfusion is often considered a static measure, but vascular flow velocity has temporal properties. For
this project, we have optimized OCTA scans to quantify vascular volume and vascular volume density, and using
sequential and registered scans, OCTA temporal variability. In the non-human primate experimental glaucoma
model, we will determine; 1. if the rate of disease progression is related to baseline global and regional measures
of vascular volume / volume density and regional OCTA temporal variability, 2. if there is loss of vascular volume
prior to inner retinal thickness, 3. if the rate of structural and functional changes are is related to the extent to
which vascular perfusion changes with IOP challenge, and 4. using post-mortem tissue, define vascular anatomy
(pericyte coverage, endothelial cell density, capillary basement membrane thickness/integrity) in healthy and
disease eyes and association with in vivo OCTA measures. Successful completion of these aims will establish if
vascular measures as quantified using OCTA can be used to determine risk of pathology, and rate of glaucoma
progression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
OCTA and Glaucoma Progression in the Non-Human Primate
-
批准号:10415689
-
项目类别:
-
资助金额:$53.76万
-
财政年份:2022
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Relating Structure to Function in Optic Neuropathies
-
批准号:10334429
-
项目类别:
-
资助金额:$37.1万
-
财政年份:2019
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Relating Structure to Function in Optic Neuropathies
-
批准号:10547776
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2019
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Retinal Nerve Fiber Layer Area in Aging and Glaucoma
-
批准号:8165940
-
项目类别:
-
资助金额:$20.66万
-
财政年份:2011
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Retinal Nerve Fiber Layer Area in Aging and Glaucoma
-
批准号:8306705
-
项目类别:
-
资助金额:$21.01万
-
财政年份:2011
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Retinal Nerve Fiber Layer Area in Aging and Glaucoma
-
批准号:8531255
-
项目类别:
-
资助金额:$21.01万
-
财政年份:2011
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Retinal Nerve Fiber Layer Area in Aging and Glaucoma
-
批准号:8720774
-
项目类别:
-
资助金额:$21.01万
-
财政年份:2011
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Biological Imaging Module
-
批准号:10724942
-
项目类别:
-
资助金额:$11.17万
-
财政年份:1997
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: